Percy Ivy

Randomized Phase II Designs

Larry Rubinstein, John Crowley, Percy Ivy, 2009, Clinical Cancer Research.

Vessel Architectural Imaging Identifies Cancer Patient Responders to Anti-angiogenic Therapy

Bruce R. Rosen, Kim Mouridsen, Percy Ivy, 2013, Nature Medicine.

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Thomas Benner, Percy Ivy, Marek Ancukiewicz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

Tracy T Batchelor, A Gregory Sorensen, Percy Ivy, 2012, Cancer research.

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

Percy Ivy, Xavier Paoletti, Laurence Collette, 2014, European journal of cancer.

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.

Percy Ivy, A. Berkenblit, S. Cannistra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Tracy T Batchelor, Thomas Benner, A Gregory Sorensen, 2007, Cancer cell.